XL228 is a novel anticancer compound designed to inhibit the insulin-like growth factor type-1 receptor (IGF1R), Src and Abl tyrosine kinases – targets that play crucial roles in cancer cell proliferation, survival and metastasis.
Investigated for use/treatment in leukemia (lymphoid) and leukemia (myeloid).
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.